Section 27a Notification

Medigene AG / Section 27a Notification . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Issuer information:

Name: Medigene AG
Address: Lochhamer Str. 11, 82152 Planegg/Martinsried
Location: Martinsried
Country: Deutschland
Security Code Number: A1X 3W0
ISIN: DE000A1X3W00

On 05 August 2014, Aviva plc informed us in accordance with Section 27a, para.1, sent.3 German Securities Trading Act (Wertpapierhandelsgesetz - WpHG), that Aviva plc has exceeded a 10% holding threshold in Medigene AG.

Aviva plc confirmed the following:

The investment is not aimed to implement strategic objectives but is aimed at generating a trading profit.There are no plans to acquire further voting rights within the next twelve months by means of a purchase or by any other means.It is not our objective to nominate onto or remove directors from the Board, but if we feel there are issues with board composition we would, in our engagement with the company encourage it to address any concerns we may have. We expect boards to be effective in safeguarding shareholder interests and they should have the right skills and experience to take the company's strategy forward. In particular we recognise the important (and independent) role of the chairman and non-executive directors in providing appropriate internal challenge to board discussions and decisions to ensure that all directors act in the best interests of the company.  We also place particular importance on boards setting appropriate standards and values for the company both in terms of corporate responsibility and also on doing the right thing in the way companies make decisions.There are no intentions to achieve a material change in the Company's capital structure, in particular as regards the ration between own funds and external funds and the dividend policy.

Within Aviva plcs total holding of 1,400,000 shares (10.07%) acquired on 22 July 2014, Aviva plc confirms that 989,823 shares are held as a beneficial (own funds) interest (7.12%) and the remaining 410,177 shares are held as a non-beneficial (external funds) interest (2.95%).

The Executive Board

Planegg-Martinsried, 06 August 2014

Contact Medigene AG

Public & Investor Relations
Julia Hofmann / Anja Clausnitzer
Email: investor@medigene.com
Tel.: +49 - (0)89 - 20 00 33 33 01

Notification as PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
HUG#1847007

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;